Cancer Drug Reimbursement Should Be Tied To Patient Outcomes, CMS' McClellan Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The CMS administrator is working with groups such as ASCO to identify ways to link cancer drug payments to physician performance and outcomes. The current payment system is "not ideal," McClellan acknowledges.